ClinConnect ClinConnect Logo
Search / Trial NCT02985710

Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan

Launched by MASSACHUSETTS GENERAL HOSPITAL · Dec 5, 2016

Trial Information

Current as of July 24, 2025

Completed

Keywords

ClinConnect Summary

Small fiber polyneuropathy (SFPN) is diagnosed through a combination of symptoms, signs and confirmatory diagnostic testing. Nerve conduction studies are not sensitive enough in most of the cases leaving the ankle skin biopsy with measurement of intraepidermal nerve fiber density (IENFD) as the main diagnostic tool. Despite its utility and reproducibility, skin biopsy is invasive, expensive and requires a central laboratory for processing and interpretation. Quantitative sudomotor axon reflex testing (QSART) is also routinely used for evaluation of small fiber neuropathy as sudomotor axons ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Males and females with confirmed disease: Fabry (by GLA enzymes and/or DNA testing) naïve and on ERT, Mitochondrial diseases (electron transport chain and/or DNA testing) or connective tissue diseases (clinical criteria and/or DNA testing when available)
  • Consenting adults (18 years and older) who agrees and consents to skin biopsy and QSART procedure
  • Exclusion Criteria:
  • Subjects with cognitive, psychiatric, or other problems that preclude informed consent.
  • Patients with history of glucose intolerance or diabetes.
  • Patient on chemotherapy
  • People with any open or bleeding wounds at any sensor plate contact surface location
  • People with any type of implantable device
  • People with missing hand(s) and/or leg(s)
  • Pregnant women or women who are uncertain about a possible pregnancy
  • Patients sensitive to chemicals used to induce sweating
  • Patients with heat intolerance
  • Patients with bleeding disorders
  • Patients on current anticoagulant therapy
  • Patients with keloids on the intended biopsy site
  • People with hypersensitivity to local amide-type anesthetics

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Amel Karaa, MD

Principal Investigator

Massachusetts General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials